Home
The War on Cancer
Cancer A – Z
Drug Approvals 2017
Articles
Conference Coverage
Editorial
Eric Rosenthal Reports
Expert Interview
Latest Articles
Publications
News
The Onco’Zine Brief
Upcoming Programs | Shows
How to Support The Onco’Zine Brief
Underwriting
The Onco’Zine Brief on PRX
The Onco’Zine Brief on Spreaker
Programs | Shows
Oncology Directory
Join Today
Event Agenda
Video
Search
About
Advertise
Advisory Board
Contact Us
Onco'Zine
Home
The War on Cancer
Cancer A – Z
Drug Approvals 2017
Articles
Conference Coverage
Editorial
Eric Rosenthal Reports
Expert Interview
Latest Articles
Publications
News
The Onco’Zine Brief
Upcoming Programs | Shows
How to Support The Onco’Zine Brief
Underwriting
The Onco’Zine Brief on PRX
The Onco’Zine Brief on Spreaker
Programs | Shows
Oncology Directory
Join Today
Event Agenda
Video
Home
Eric Rosenthal Reports
Eric Rosenthal Reports
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Why Were Top HHS Officials? Interviews Thwarted by Their Press Offices?
Eric T. Rosenthal
-
March 5, 2019
Dr. Brawley Goes to Baltimore?and Washington
Jose Baselga Resigns as Co-Editor-in-Chief of Cancer Discovery
Professional Societies Disclose Their Disclosure Policies, But Why Won?t Some Discuss Them?
Otis Brawley Discusses Life After Leaving the American Cancer Society
How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga?s...
Eric T. Rosenthal
-
October 9, 2018
How a Hollywood-and-Scientist Dream Team Created a New Paradigm in Collaborative...
Eric T. Rosenthal
-
September 22, 2018
Mike Caligiuri Discusses Upcoming AACR Meeting, Cancer Health Equality, and Sudden...
Eric T. Rosenthal
-
April 12, 2018
Why Academia Wasn’t Ready to Build Big Data Systems – A...
Eric T. Rosenthal
-
April 10, 2018
Eric Rosenthal Reports | A Personal Remembrance of Two Giants of...
Eric T. Rosenthal
-
April 3, 2018
LATEST
Lung Cancer Among the Most Likely Conditions to Harm Patients who are Misdiagnosed
Peter Hofland, Ph.D
-
July 12, 2019
Japan Approves Olaparib as First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Peter Hofland, Ph.D
-
July 10, 2019
FDA Accepts Supplemental Biologics License Applications for Pembrolizumab
Peter Hofland, Ph.D
-
July 10, 2019
SNDX-5613 Shows Strong Tumor Growth Inhibition and Improved Survival in Preclinical Models –
Peter Hofland, Ph.D
-
July 10, 2019
US FDA to Review Isatuximab as a Potential Treatment for R/R Multiple Myeloma
Peter Hofland, Ph.D
-
July 10, 2019
